Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort. [electronic resource]
Producer: 20200403Description: 278-286.e1 p. digitalISSN:- 1938-0690
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cohort Studies
- Female
- Humans
- Imidazoles -- therapeutic use
- Lung Neoplasms -- drug therapy
- MAP Kinase Kinase Kinases -- antagonists & inhibitors
- Male
- Middle Aged
- Mutation -- genetics
- Oximes -- therapeutic use
- Proto-Oncogene Proteins B-raf -- antagonists & inhibitors
- Pyridones -- therapeutic use
- Pyrimidinones -- therapeutic use
- Survival Analysis
- Vemurafenib -- therapeutic use
No physical items for this record
Publication Type: Evaluation Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.